MM_Hub: CONGRESS|#EHA2021|Neils van de Donk reported results from 1st in-human, Phase-1 study of teclistamb in R/R-MM pts. At the RP2D of weekly 1500 μg/kg SC, it was well-tolerated with durable deepening responses #mmsm, #myeloma, Amsterdam University Medical Center, Netherlands

by | Jun 11, 2021 | Twitter | 0 comments

CONGRESS|#EHA2021|Neils van de Donk reported results from 1st in-human, Phase-1 study of teclistamb in R/R-MM pts. At the RP2D of weekly 1500 μg/kg SC, it was well-tolerated with durable deepening responses #mmsm, #myeloma, Amsterdam University Medical Center, Netherlands pic.twitter.com/1kASnRVJnQ

— Multiple Myeloma Hub (@MM_Hub) June 11, 2021

Submit a Comment